Chromosome band 1 1 q23 is frequently involved in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) de novo, as well as in myelodysplastic syndromes (MDS) and lymphoma. Five percent to 15% of patients treated with chemotherapy for a primary neoplasm develop therapy-related AML (t-AML) that may show rearrangements, usually translocations involving band 1 1 q23 or, less often, 21 q22. These leukemias develop after a relatively short latent period and often follow the use of drugs that inhibit the activity of DNA-topoisomerase II (topo 11). We previously identified a gene, MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia), at 1 1 q23 that is involved in the de novo leukemias. We have studied 17 patients with t-MDS/t-AML, 12 of whom had cytogenetically detectable 1 1 q23 rearrangements. Ten of the 12 t-AML
A ments of chromosome band 1 lq23 are observed in human de novo acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) as well as in lymphoma and myelodysplastic syndromes (MDS). Translocations involving 1 lq23 with lq21, 6q27, 9p22, lop1 1-15, or 17q21-25 are observed primarily in AML.',' The t(4; I l)(q2 l;q23) and t( 11;19)(q23;pl3.3) are associated with ALL as well as with mixed-lineage and biphenotypic leukemias.'-3 In addition to the 1 lq23 rearrangements associated with leukemia that arises de novo, balanced translocations involving this band are observed in AML (usually with monoblastic or myelomonocytic characteristics) that occasionally develops after cytotoxic treatment for a primary n e~p l a s m .~-~ The t(9;l l)(p22;q23) and the t( 1 1;19) are among the most common 1 1 q23 rearrangements observed in therapy-related AML (t-AML).7*8 These patients develop overt leukemia after a relatively short latent period, most often after treatment with drugs that target DNA-topoisomerase I1 (topo 11). These drugs include, primarily, the epipodophyllotoxins, such as etoposide (VP-16) and teniposide , and the anthracyclines, such as daunorubicin, doxorubicin hydrochloride (adriamycin), and 4-epidoxorubicin. The clinical and cytogenetic features of this form of t-AML are distinct from the more common t-AML or t-MDS that follows treatment with alkylating agents, often presenting with losses of whole chromosomes 5 or 7 or deletions of the long arm of these c h r o m~s o m e s . ~~~ We have shown that a yeast artificial chromosome (YAC) containing the CD3D and CD3G genes and DNA extending approximately 300 kb distal to these genes, on chromosome 11, was split in leukemia cells from patients with t(4;l l), t(6; 1 l), t(9; 1 I), and t( 1 1 ; 19), indicating a clustering of breaks in these common 1 lq23 rearrangements.' Genomic probes isolated from a library prepared from this YAC identified a large transcript that spans the breakpoint region. The gene was named MLL for myeloid-lymphoid or mixedlineage leukemia." We cloned a 0.74-kb cDNA BamHI fragment that detects rearrangements in DNA digested with BamHI on conventional Southern blots in all patients with the most common llq23 translocations as well as with more rare I lq23 rearrangements.'','Z The 0.7-kb cDNA probe (MLL0.7B) identifies a single 8.3-kb genomic BamHI fragment, indicating that the breakpoints are clustered in this fragment (Fig 1) . Others have cloned the same gene and have called it ALL-I,l3 Htrx, I4 or HRX.I5 The gene is transcribed from centromere to telomere.I2
Most analyses reported to date have included only patients who developed AML de novo. We report here the molecular analysis of 17 patients diagnosed with t-AML or t-MDS. The majority of the patients received top0 11-targeting drugs, often in combination with alkylating agents, for their primary neoplasm. Twelve patients had 1 lq23 rearrangements detected cytogenetically. Nine of these leukemia samples had DNA rearrangements on Southern blot analysis with the MLL0.7B probe. In addition, we observed a significant association between prior treatment with top0 I1 inhibitors and MLL gene rearrangements in t-AML.
MATERIALS AND METHODS
Peripheral blood or bone marrow obtained with informed consent from patients developing AML after cytotoxic treatment for a prior neoplasm was frozen for DNA analysis. All such patients who were studied at the University of Chicago with material stored at the time of diagnosis and who exhibited a chromosomal abnormality involving 1 lq23 were included. These samples were obtained from 1985 to 1992. Similar material was provided by the University Hospital, Copenhagen, Denmark, including Ficoll-Isopaque-isolated mononuclear cells or granulocytes from the same patients. We also analyzed 5 patients who lacked cytogenetic I lq23 rearrangements, but who developed t-AML or t-MDS (with monoblastic features) after treatment with top0 11-reactive drugs or after other types of chemotherapy. Cytogenetic analysis was performed using trypsin-Giemsa banding.
DNA analysis. DNA was extracted from leukemia cells using standard techniques. Ten micrograms of each sample was restricted with BamHI or HindIII, separated by electrophoresis on 1% agarose gels, and transferred to Genescreen (New England Nuclear Research Products, Boston, MA) nylon membranes. The MLL0.7B probe was cloned from a cDNA library as described elsewhere.12
The probes corresponding to the extreme 5' and 3' ends of the 8.3-kb BamHI fragment were made by polymerase chain reaction (PCR) amplification of MLL0.7B sequences." Probes were 32P-labeled by the random priming method16 (Pharmacia, Piscataway, NJ). Hybridization to Southern blots was performed with 50% formamide at 42°C. Blots were washed to a final stringency of I X or 0.1 X SSC, 1 % sodium dodecyl sulfate (SDS), at 65"C, beforeautoradiography.
RESULTS
DNA from 17 patients with t-AML or t-MDS was analyzed for rearrangements of the MLL gene. Clinical information for all patients is presented in Table 1 . Included are 12 samples (nos. 1 through 12) that showed cytogenetically detectable 1 lq23 rearrangements ( Table 2 ). Ten of these 12 patients had received chemotherapy that included top0 I1 inhibitors. On Southern blot analysis, the 0.74-kb BamHI MLL cDNA fragment, MLL0.7B, detected DNA rearrangements in 9 of these I O patients. All 9 showed balanced translocations of 1 lq23, cytogenetically. The other patient (no. 12) who showed no rearrangement with the probe had an unbalanced translocation (Tables 2A and 3 , Fig 2, and data not shown). Two patients who had unbalanced rearrangements of 1 lq23 (nos. 10 and 1 1 with interstitial deletions q13-14q23) had received no top0 I1 inhibitors. No DNA rearrangements were detected in these patients (Tables 2B  and 3) . A third subset of 5 patients (nos. 13 through 17) presented with t-AML or t-MDS but had no cytogenetically detectable llq23 rearrangement. Four of the 5 (nos. 13 through 15 and 17) had received top0 I1 inhibitors, whereas 1 (no. 16) had received only other types of chemotherapy. Three (nos. 14, 16, and 17) presented with M4 t-AML. No sample from this group showed any rearrangements with the MLL0.7B probe. Some ofthe patient samples were flowsorted into granulocytes and mononuclear cells. In the two cases in which rearrangements were noted in these samples (nos. 7 and 9), both types of cells exhibited the rearrangement.
We reported previously that the MLL0.7B probe detected two rearranged bands, originating from both derivative chromosomes, in approximately 70% of the samples of leukemia de novo, as well as an 8.3-kb BamHI germline fragment." Probes made from each end ofthe MLL0.7B cDNA fragment, when hybridized separately, detected only one or the other of the two rearranged bands, indicating that each probe hybridized to the MLL gene on either the derivative 11 [der( 1 I)] or the derivative chromosome formed with the other translocation partner. In samples in which only one rearranged band was detected, exon sequences telomeric to the breakpoint were shown to be deleted, whereas the centromeric exons were always retained." We have analyzed the t-AML samples in a similar manner. Of the 9 samples that showed rearrangements with the MLL0.7B probe, 6 had two rearranged bands, whereas 3 had a single rearrangement (Fig 2 and Table 2A ). In each case in which two rearranged bands were detected, the centromeric and telomeric probes identified a single rearranged band corresponding to the der( 1 1) and the other derivative chromosome, respectively (data not shown). In the 3 cases in which only one rearranged band was detected with the MLL0.7B probe, 1 (no. 9) exhibited a deletion of exon sequences telomeric to the breakpoint, whereas 2 (nos. 3 and 7) showed a deletion of exon sequences centromeric to the breakpoint (data not shown).
DISCUSSION
We recently identified the MLL gene, which is rearranged in both common and rare 1 lq23 translocations in acute leukemia de novo."," We now have detected molecular rearrangements in the same 8.3-kb region of the MLL gene in 9 of 17 patients who developed t-AML (Table 2A, Fig 2, and data not shown).",I2 Moreover, we have detected MLL rearrangements in 9 of 10 t-AML patients with 1 lq23 translocations who had received chemotherapy that included top0 11-targeting agents (Table 3 ). All 9 patients had balanced translocations, whereas a single patient (no. 12) who had an unbalanced 1 1 q23 translocation cytogenetically had a germline BamHI fragment with the MLL0.7B probe. We studied this patient by fluorescence in situ hybridization (FISH) with a series of DNA probes from 1 lq23. We observed that the breakpoint is proximal to the entire MLL locus; thus, the rearrangement in this sample involves another gene or genes, not simply another region of MLL." The 2 patients who also had leukemia cells with cytogenetic 1 lq23 rearrangements, but who had not received top0 I1 inhibitors, did not have rearrangements of this gene. We examined an additional 5 t-AML patients whose cells lacked 1 lq23 aberrations but who had a phenotypically similar (monoblastic leukemia or MDS) secondary disease. Four of the 5 had received top0 11-inhibiting drugs. We wanted to determine whether any of this group might have a cryptic MLL rearrangement. However, no MLL rearrangement was observed in any of these patients (Tables 1B and  2B ). der( l)t(l;7)(pl 1 ; p l l),-7
Abbreviations: mono, mononuclear cells; gran, granulocytes; G, germline fragment; R, rearranged fragment.
Samples from 3 patients were flow sorted into mononuclear cells and granulocytes. In the 2 samples (patients no. 7 and 9, with t-AML, and M4 and M5b, respectively) that showed MLL rearrangements, the same rearranged band was present in both cell types. Patient no. 1 1 (with MDS) showed no rearrangement in either cell type. Our data suggest that the recombination event involving the MLL gene occurs in a monocytic-granulocytic (or earlier) precursor cell and that the rearrangement does not inhibit the differentiation of granulocytic precursors present in the mononuclear fraction ofleukemia cells. The involvement ofMLL in both myeloid and lymphoblastic leukemias as well as in mixed-lineage and biphenotypic leukemias suggests that some of the recombination events involving this gene could occur even earlier in hematopoietic differentiation, perhaps in a pluripotent stem cell.
In our previous study of MLL rearrangements in AML/ ALL de novo, we observed that, in about 30% of the samples, one or more exons 3' (telomeric) of the breakpoint cluster region are deleted, whereas the 5' (centromeric) exons are always retained." The preservation of the 5' exons as well as the consistent conservation of the der (1 1) chromosome in variant translocations (involving a third chromosome) suggests that the der (1 1) contains the critical junction for the development of these leukemias." We have studied 2 t-AML samples that showed deletions of at least some of the centromeric exons of the 8.3-kb breakpoint region. This result may indicate that there is a difference in t-AML/tMDS and acute leukemias that develop de novo with respect to the critical regions of the MLL protein. However, our observations may simply show that exons important for the development of both types of leukemias are further centromeric to the breakpoint cluster region.
Although the MLL gene is rearranged in the majority of 1 lq23 translocations, a human lymphoma cell line, RC-K8, with a t ( I 1; 14)(q23;q32) , has been shown to involve another gene, RCK, that is I10 to 400 kb telomeric to the MLL locus.2o Another study showed that a patient with a null-cell acute lymphoblastic leukemia with an (1 1;14)(q23;ql I ) translocation had a breakpoint on 11 that is distal to both MLL and RCK, involving an as yet unidentified gene.2' Another gene, PLZF, was identified at the junction of a t( I I; 17)(q23;q2 1) translocation in a patient with acute promyelocytic leukemia. The rearrangement resulted in a fusion of this gene with the retinoic acid receptor CY gene on chromosome 17. 22 Thus, there are a number of other genes involved in the 1 lq23 rearrangements that are observed in human leukemia cells.
The leukemogenic nature of chemotherapeutic drugs has been recognized for a number of years. The earliest reported cases of t-AML were attributed to prior treatment with alkylating agents. These patients usually present with MDS after a median latent period of approximately 5 years. Cytogenetic features include a loss of chromosomes 5 and/ or 7 or the long arm of these chromosomes. The MDS progresses to overt AML that is relatively resistant to chemotherapy; the prognosis is poor and the survival time is short. 23224 Ratain et a12' first reported the association of high doses of the epipodophyllotoxin, etoposide, for treatment of a lung cancer, with the subsequent development of t-AML. This secondary leukemia appeared to be distinct from that induced by alkylating agents, having predominantly monoblastic features, involvement ofchromosome band I lq23, a short latent period, and a more favorable prognosis.25 We and others have shown that this second subtype of t-AML is often associated with balanced translocations of I lq23, and occasionally with translocations affecting 2 lq22, after treatment with a number of drugs that, similar to etoposide, target top0 II.5-8 Our molecular study confirms the previous cytogenetic observations with respect to this type of t-AML/ t-MDS. We observed a significant association (P = .01, Fisher's exact test) of MLL rearrangements and prior use of top0 11-reactive therapy. As expected, all ofthe patients with Numbers of patients in each category are listed first, with patient numbers in parentheses. All patients listed had cytogenetic 1 1 q23 rearrangements (P = .01, Fisher's exact test).
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BamHl MLL rearrangements had balanced translocations and developed overt t-AML after a relatively short latency period. Those patients who showed no MLL involvement had unbalanced rearrangements, rare translocations, or normal patients with MLL rearrangements karyotypes and developed t-MDS or t-AML after a much longer latent period (Tables I and 2 For personal use only. on October 23, 2017. by guest www.bloodjournal.org From 3710 GILL SUPER ET AL in dividing neoplastic cells, the actual biologic activities of these drugs vary in vivo. Both the epipodophyllotoxins and the anthracyclines appear to stabilize the DNA-enzyme complex after double-strand cleavage, resulting in the accumulation of DNA double-strand break^.^^,^^ However, the anthracyclines, such as adriamycin, act by intercalating into the DNA, whereas the epipodophyllotoxins do not intercalate. In addition, in at least one cell line (HL60), the activities of these two types of drugs differ. Treatment with VM-26 results in degradation of DNA in S-phase, whereas doxorubicin causes arrest in Sand G2 with no such degradation of the DNA. 28 In another study, the epipodophyllotoxins have been implicated in the direct or indirect induction of apoptosis in addition to causing DNA double-strand breaks.2g Another group of drugs, known as the dioxopiprozanes, has recently been associated with t-AML. In one study, the most frequently detected chromosome rearrangements were the t( 15;17)(q22;q12) and the t(8;21)(q22;q22). These drugs appear to inhibit the catalytic activity of top0 I1 by competing with DNA for direct binding to the enzyme; thus, they would inhibit, rather than induce, double-strand breaks. 30 The association of the use of top0 I1 inhibitors with the development of t-AML may provide insights into the mechanism of aberrant recombination at I lq23 (and 21q22) in both t-AML and t-AML de novo. VP-16 and VM-26 have been observed to induce nonrandom chromosome aberrations, rearrangements of specific genes, and reciprocal exchanges between nonhomologous chromosomes in vit1-0.~'"~ It has been proposed that, in the presence of these drugs, top0 I1 molecules become trapped and covalently integrated in the DNA, thus becoming more abundant and available to mediate aberrant recombination. Both prokaryotic and eukaryotic purified top0 I1 proteins have been shown to mediate recombination between nonhomologous DNA molecules in vitro.34 Finally, top0 I1 has been implicated in aberrant recombination events as a component of chromatin structure, specifically as a major scaffold attachment region (SAR) protein. 35 SARs have been localized to translocation breakpoint junctions, some of which have been shown to bind top0 I1 specifically and to act as "hot spots" for double-strand cleavage.36
The genomic MLL breakpoint cluster region (8.3-kb BamHI fragment) has recently been sequenced. Its overall sequence composition is extremely AT-rich and includes several Alu repeats. More importantly, the fragment contains several in vitro and in vivo consensus binding sites for top0 II. 37 At this time, we speculate that the region may contain a number of active top0 I1 binding sites or may be especially prone to cleavage, acting as a "hot spot" for double-strand breakage, which, under the appropriate conditions, leads to aberrant recombination with a number of other chromosomal regions. Certain selected recombinations in hematopoietic cells would provide a proliferative advantage that ultimately results in leukemia. Evidence for translocation breakpoints occurring at or near top0 I1 sites has recently been reported for the t( 15; I 7). 38 In summary, rearrangements of the MLL gene are observed in t-AML, especially after treatment for a primary tumor with top0 11-reactive drugs. The breakpoint cluster region within the MLL gene is the same as that observed in AML de novo. We are currently investigating the chromatin structure of the breakpoint region and testing for evidence of the ability of top0 I1 to bind and to cut in this region. These studies should lead to an understanding of the possible role of top0 I1 in the frequent illegitimate recombination events that occur both in AML de novo and in t-AML.
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